Clinical Trial Update: A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of GSK2256098 with trametinib in advanced pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• GSK2256098
• Trametinib (trametinib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Pancreatic Cancer, Adenocarcinoma | Phase 2 | Status: COMPLETED